Summary & Overview
HCPCS J7620: Albuterol and Ipratropium Nebulized, DME Administration
HCPCS Level II code J7620 identifies an FDA‑approved, pre‑formulated inhalation combination of albuterol (up to 2.5 mg) and ipratropium bromide (up to 0.5 mg) supplied as a non‑compounded, DME‑administered product. This code matters nationally because combination bronchodilator therapy is commonly used for acute and chronic obstructive airway management and billing clarity affects access and reimbursement across settings where durable medical equipment is used. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what J7620 represents clinically and operationally, the typical sites of service where the product is administered, and the scope of payers included in the coverage review. The publication provides benchmarks and policy-relevant context for billing and claims adjudication of DME‑administered nebulized combination bronchodilator therapy, summarizes common modifier usage patterns, and flags areas where payers often require clinical documentation or specific DME coding. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7620 describes a ready-to-use, FDA-approved combination inhalation product containing albuterol (up to 2.5 mg) and ipratropium bromide (up to 0.5 mg) provided as a final non‑compounded product. The description indicates the medication is administered through durable medical equipment (DME), specifically via an inhalation delivery system.
Service type: Respiratory combination bronchodilator therapy (nebulized solution) administered as a DME‑delivered treatment.
Typical site of service: Outpatient settings where DME is used, including home health and clinic infusion/respiratory therapy areas. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual presenting to an outpatient infusion clinic, emergency department, or skilled nursing facility with acute exacerbation of chronic obstructive pulmonary disease (COPD) or an acute asthma exacerbation with bronchospasm unresponsive to handheld inhalers. The patient is assessed by a clinician (pulmonologist, emergency physician, or respiratory therapist). Vitals and pulse oximetry are monitored. A decision is made to administer nebulized combination therapy of albuterol and ipratropium bromide using durable medical equipment (nebulizer supplied by a DME vendor). The medication billed with J7620 is the FDA-approved premixed albuterol up to 2.5 mg with ipratropium bromide up to 0.5 mg solution, non-compounded, delivered via the facility’s or patient’s DME nebulizer. Typical workflow: evaluate airway/breathing, document indication and response, set up nebulizer with the J7620 ampule or single-use vial, administer over standard treatment time (typically 5–15 minutes), monitor for improvement or adverse effects (tachycardia, tremor, dry mouth), document start/stop times, and disposition (return to baseline, observation, admission, or discharge). Billing may occur for each unit of drug administered per facility policy and payer rules; modifiers may be appended as appropriate for place of service, provider status, or service circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 |